R&D channel feed

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

7 years ago
Pharma

#AS­CO18: Ab­b­Vie con­vinces one top an­a­lyst that its $6B 'megablock­buster' Ro­va-T is worth­less

7 years ago

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

7 years ago

#AS­CO18: Bris­tol-My­ers takes an­oth­er stab at a pos­i­tive im­pres­sion for Check­Mate-227

7 years ago

Nek­tar wants every­one to stay calm as they car­ry on with NK­TR-214, but #AS­CO18 spurs a stam­pede

7 years ago

Stan­ford spin­out Forty Sev­en ar­rives at AS­CO with a snap­shot of promis­ing CD47 da­ta — and a $115M IPO in hand

7 years ago
Financing

Roche dumps its PhI­II PI3K ef­fort on taselis­ib af­ter re­searchers track poor sur­vival edge, harsh side ef­fects for breast can­cer

7 years ago

Mer­ck­'s Keytru­da builds a com­mand­ing lead in front­line lung can­cer with da­ta from two more land­mark tri­als

7 years ago

Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic can­cer drug suc­cess

7 years ago
Pharma

Roche boasts of stalling lung can­cer with Tecen­triq/chemo com­bo -- but ri­val Mer­ck stays out front

7 years ago

Blue­bird, Cel­gene add a promis­ing chap­ter to their suc­cess sto­ry with BC­MA-tar­get­ing CAR-T — and turn it around with in­vestors

7 years ago

Roche dumps its late-stage SMA drug af­ter gam­bling up to $545M-plus on the pro­gram

7 years ago

Bay­er scru­ti­nizes R&D group's pro­duc­tiv­i­ty as staffers fear lay­offs in wake of a re­vamp

7 years ago
Pharma

J&J racks up a fresh set of pos­i­tive piv­otal da­ta for de­pres­sion drug es­ke­t­a­mine — but ques­tions linger on safe­ty

7 years ago

Iron­wood dodges a Den­ner board seat, but the ac­tivist in­vestor still has words of ad­vice

7 years ago
People

ScPhar­ma's stock droops on 'd­e­fi­cien­cies' as FDA toss­es back heart fail­ure drug ap­pli­ca­tion

7 years ago

Madri­gal shares soar on promis­ing PhII NASH da­ta, stok­ing hopes for a new con­tender

7 years ago

Gilead and Gala­pa­gos bag promis­ing PhII da­ta for star im­munol­o­gy drug fil­go­tinib — boost­ing late-stage fo­cus

7 years ago

Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

7 years ago
Pharma

FDA slaps a clin­i­cal hold on sick­le cell IND filed for a new gene ther­a­py from Ver­tex and CRISPR Ther­a­peu­tics

7 years ago

PhRMA's new re­port counts each can­cer drug in the US pipeline, which has now swelled to over 1,000 in the clin­ic

7 years ago

J&J hus­tles Leg­end’s promis­ing BC­MA CAR-T in­to PhI/II tri­al, win­ning an FDA green light to be­gin re­cruit­ing pa­tients

7 years ago
Pharma

FDA moves Sage’s post­par­tum de­pres­sion drug brex­anolone in­to reg­u­la­tors’ busy pri­or­i­ty lane

7 years ago
Pharma

As­traZeneca writes off its sec­ond piv­otal COPD tri­al for Fasen­ra, killing ex­pan­sion plans

7 years ago
First page Previous page 269270271272273274275 Next page Last page
A service from the Financial Times